(Q82100704)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22011907%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

title

A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22011907%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

main subject

phase III clinical trial

1 reference

randomized controlled trial

inferred from title

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22011907%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Bruce E Strober

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22011907%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

Kenneth B Gordon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22011907%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Richard G Langley

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22011907%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Alice B Gottlieb

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22011907%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Gerald G Krueger

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22011907%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

David A Williams

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22011907%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Yihua Gu

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22011907%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Joaquin M Valdes

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22011907%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

language of work or name

English

0 references

publication date

20 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22011907%20AND%20SRC:MED&resulttype=core&format=json

Journal of Investigative Dermatology

14 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22011907%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

volume

132

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22011907%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22011907%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

page(s)

304-314

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22011907%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/jid.2011.304

14 January 2020

exact match

0 references

cites work

The IL-23/Th17 axis in the immunopathogenesis of psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Risk of Myocardial Infarction in Patients With Psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Inflammation, atherosclerosis, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

The immune system in atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

IL-23 promotes tumour incidence and growth

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

IL-12 and IL-23: master regulators of innate and adaptive immunity.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Psoriasis: a possible risk factor for development of coronary artery calcification.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Enhanced photocarcinogenesis in interleukin-12-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

https://api.crossref.org/works/10.1038%2FJID.2011.304

1 reference

7 January 2021

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Increased atherosclerotic lesions and Th17 in interleukin-18 deficient apolipoprotein E-knockout mice fed high-fat diet

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021

Expression of interleukin-12 is increased in psoriatic skin

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.304

7 January 2021